Obiettivo Intestinal homeostasis is a complex event that relies on different interactions between the host and the commensal flora, also called microbiota. The microbiota is a source of gene products that are required for several functions linked to digestion and energy harvest, thus it has to be tolerated, but at the same time controlled. We have shown that the capacity to tolerate the microbiota is linked to a close interaction between epithelial cells, that are the first line of defence against luminal microorganisms, and specialized immune cells called dendritic cells, that acquire a tolerogenic phenotype and drive the development of T regulatory cells, capable to control the development of inflammatory responses to bacteria. We have identified several effectors mediating this control and focused on a cytokine called thymic stromal lymphopoietin (TSLP) that is released constitutively by epithelial cells and is strongly downregulated in inflammatory bowel disease (IBD). By contrast, in other inflammatory disorders like allergy or asthma, TSLP has been shown to be upregulated and to mediate disease.This apparent controversy is solved when considering that TSLP comes in two different isoforms: a short (sTSLP) and a long (lTSLP). sTSLP has been completely neglected in the literature as most of the reagents do not distinguish it from lTSLP. Within the ERC project Dendroworld, we have generated all the tools to study the function of these two isoforms. We discovered that in IBD there is an inverse correlation between sTSLP and lTSLP. lTSLP is drastically upregulated by recruited immune cells, while sTSLP is downregulated in epithelial cells. Hence, we hypothesized and confirmed that the two isoforms had different activities, with the sTSLP being anti-inflammatory and lTSLP being inflammatory.In this POC we propose scientific and commercialization activities to bring sTSLP to the market as a new class of anti-inflammatory drugs capable of re-establishing immune homeostasis. Campo scientifico medical and health sciencesclinical medicinepneumologyasthmamedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesbasic medicineimmunologymedical and health sciencesclinical medicineallergologymedical and health sciencesbasic medicinephysiologyhomeostasis Programma(i) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Argomento(i) ERC-OA-2012-PoC - European Research Council ERC Proof of Concept Invito a presentare proposte ERC-2012-PoC Vedi altri progetti per questo bando Meccanismo di finanziamento CSA-SA(POC) - Supporting action (Proof of Concept) Coordinatore ISTITUTO EUROPEO DI ONCOLOGIA SRL Contributo UE € 127 657,00 Indirizzo Via filodrammatici 10 20121 Milano Italia Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Ilaria Foti (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Beneficiari (2) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto ISTITUTO EUROPEO DI ONCOLOGIA SRL Italia Contributo UE € 127 657,00 Indirizzo Via filodrammatici 10 20121 Milano Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Ilaria Foti (Ms.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS Italia Contributo UE € 19 260,00 Indirizzo Via adamello 16 20139 Milano Mostra sulla mappa Regione Nord-Ovest Lombardia Milano Tipo di attività Research Organisations Contatto amministrativo Carlo Raimondi Cominesi (Mr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato